Substantial evidence suggests that spontaneous thrombolytic activity of blood is an effective mechanism for protection against tissue damage that is the consequence of lasting arterial occlusion. Despite the generally held belief that coronary artery disease and stroke are preventable, a promising avenue of prevention, namely the identification and prophylactic treatment of those at risk of inefficient spontaneous thrombolysis, has been neglected. This is mainly due to the lack of physiologically relevant test. A recently described technique allows the measurement of spontaneous thrombolysis, that is, lysis of an autologous platelet-rich thrombus in the absence of added plasminogen activators. Early results suggest that this test may have significant clinical potential both in identifying those at risk from fatal thrombotic event and in finding new therapeutic avenues of improving spontaneous thrombolytic activity.
The extent of tissue damage and the clinical outcome of an arterial thrombotic event is determined by the result of two opposing processes, namely the formation and the degradation of the platelet-rich thrombus. Thrombosis is initiated by vessel wall injury and propagated by flow disturbances (high shear stress) and the release of aggregating agents from platelets and red cells. Coagulation is activated at an early phase of thrombosis. Thrombin is generated, amplifying the initial platelet aggregation and conferring structural stability on the otherwise fragile thrombus, by formation of fibrin mesh. Even in response to the most intense thrombogenic stimuli, such as deep vessel wall injury, the build-up of an occlusive thrombus takes time. The growth and stabilization of the platelet mass must overwhelm the powerful disruptive mechanical (shear stress, high arterial pressure) and enzymatic forces (fibrinolysis), which limit thrombus growth by embolization. Once the artery becomes occluded, only thrombolysis can restore patency and flow.
Therapeutic thrombolysis with plasminogen activators has opened up a new chapter in the prevention of lasting tissue damage due to arterial thrombosis. Although extremely effective, therapeutic thrombolysis is not a panacea, since it has many limitations, such as the narrow time-window of application, risk of hemorrhage, the uncertainty of reperfusion, and cost. Primary angioplasty overcomes many of the limitations of therapeutic thrombolysis and recent evidence appears to indicate that it is superior to thrombolysis (1, 2) .
EVIDENCE FOR EXISTENCE
Serial angiography of the coronary artery after the onset of symptoms of acute myocardial in-farction (AMI) has provided the most convincing evidence for the existence of spontaneous thrombolysis. Studies in large numbers of patients describe spontaneous reperfusion of the infarct-related artery, which occurs frequently in AMI and is associated with significant myocardial salvage in the absence of thrombolytic therapy or percutaneous coronary intervention. Total coronary occlusion, as evidenced by coronary arteriography, was observed in 90% to 95% of patients who were evaluated within 4 hours of the onset of symptoms and this fell considerably by 12 to 24 hours of onset, to 50% to 65% (3) (4) (5) (6) . Spontaneous recanalization in AMI patients undergoing primary angioplasty, as evidenced by Thrombolysis In Myocardial Infarction [TIMI] anterograde 2 flow on the preintervention angiogram, was associated with faster coronary flow, smaller infarct size, and better clinical outcome after primary angioplasty (7) . In addition, several case reports have documented spontaneous lysis of arterial thrombi in various clinical settings (8) (9) (10) (11) (12) (13) . Furthermore, a local myocardial profibrinolytic response has been documented following regional myocardial ischemia (14) and spontaneous thrombolysis of traumatic arterial thrombi has also been demonstrated (15) . Markers of activated spontaneous thrombolysis have also been detected in the injured area of spontaneous brain damage in stroke-prone rats (16) .
IMPORTANCE
Nature has provided effective physiologic protection against a variety of harmful events. While hemostatic platelet function is physiologic, arterial occlusion due to a platelet-rich thrombus formation is pathologic. It has long been suspected that spontaneous (endogenous) thrombolytic activity of blood is the physiologic protection against excessive, pathologic intravascular coagulation.
AMI has been regarded a result of the failure of timely spontaneous thrombolysis (17) . A recent publication reporting on local myocardial profibrinolytic response following regional myocardial ischemia concluded that such profibrinolytic response might serve as a prompt defense against coronary thromboembolic events (14) . Early administration of thrombolytic therapy with rt-PA for ischemic stroke significantly improves outcome. High levels of thrombin-activatable fibrinolysis inhibitor (TAFI) were found in the acute phase of ischemic stroke, the highest levels observed in those cases with neurologic deterioration (18) . There is also evidence for the hypothesis that disturbances in fibrinolysis precede a cerebrovascular event (19) .
POSSIBLE MECHANISMS
The lysis of the fibrin network, which stabilizes the platelet-rich thrombus, can be achieved either by plasmin-dependent or -independent pathways, or a combination of both. Vascular endothelial cells synthesize activators and inhibitors of fibrinolysis, such as t-PA, u-PA, and plasminogen activator inhibitor-1 and -2 (PAI-1 and PAI-2, respectively). Endothelial cells respond quickly to ischemia, releasing these pro-and anti-fibrinolytic compounds into the circulation. The release is probably nitric oxide (NO) regulated (20) . However, the overall effect of the simultaneous release of both fibrinolytic stimulators and inhibitors is difficult to assess. The frequently observed spontaneous lysis of large pulmonary thromboemboli points to the existence of potent fibrinolytic activity in the human pulmonary artery. Recent findings support this assumption, indicating that the balance between t-PA and PAI-1 is shifted in human pulmonary artery to favor net plasminogen activator activity (21) . Polymorphonuclear leucocytes have been shown to accumulate within the thrombus at an early phase of thrombogenesis, attacking fibrin both by plasminogen-dependent and -independent ways. The latter is mediated by the release of serine proteases, including elastase, cathepsin G, and proteinase 3 (22) . Monocyte infiltration of the developing thrombus has been demonstrated in experimental models of thrombosis. The release of plasminogen activators from monocytes may contribute to the resolution of thrombus (23) .
GLOBAL IN VITRO ASSESSMENT OF FIBRINOLYTIC ACTIVITY
Realizations that clot lysis occurs in vivo but not in vitro has hampered the development of a global in vitro test. While direct observation of a thrombus in the microcirculation or objective measurement of thrombus size in an occluded artery or vein demonstrated rapid spontaneous lysis, dissolution of a clot in vitro is an ex-tremely slow process. Lysis of clots prepared from native or citrated whole blood by the addition of thrombin was measured by the release of 125 I-fibrinogen degradation products. The degradation of thrombus was 10% or less at 20 hours (24), while 50% lysis was observed at 3.5 to 4.7 days (25) . It is obvious that such an assay cannot satisfy the need of clinical practice. Frustration over the resistance of clot to lysis in vitro led to the measurement of lysis of isolated plasma euglobulin protein (euglobulin lysis time; ELT). In this test, citrated platelet-poor plasma is precipitated with cold acetic acid, the precipitate re-dissolved, the euglobulin solution clotted with thrombin and the clot incubated at 37°C. The clot is observed for lysis at regular intervals. The ELT varies from 1.25 to 12.0 hours in normal ambulatory volunteers (26) . During precipitation, natural fibrinolysis inhibitors are removed and therefore ELT provides only a measure of plasminogen activation in the absence of inhibitors. Aside from the laborious procedure and lengthy evaluation time, the main limitation of this assay is the lack of inhibitors. Despite the recent development of a computerized, semi-automatic 8-channel device (27) , ELT seems to remain a research tool. Another in vitro technique, thrombelastography, monitors the formation and dissolution of a blood clot. Because of the very slow normal clot-lysis, thrombelastography can only detect hyper-fibrinolysis and the effect of plasminogen activators.
Recent reports provide some insight into the peculiar resistance of blood clot to lysis in vitro. As whole blood (plastic) clotting time is 15 to 20 minutes, with great individual variation, thrombin is added to citrated or native blood to induce rapid clotting. However, thrombin-induced clots differ from clots formed spontaneously under clinical conditions (28) . rtPA-induced thrombolysis promotes rapid reperfusion in animals embolized with spontaneously formed clots but not in those embolized with thrombin-induced clots. This differing susceptibility to lysis was explained by the different mechanical and possibly molecular consequences of clot preparation. Further, a new inhibitor of fibrinolysis, which decreases plasminogen binding to the fibrin surface, was discovered and named thrombin-activatable fibrinolysis inhibitor (TAFI) (29) . TAFI formation following thrombin-induced clotting might explain the resistance of such clots to lysis.
FACTORIAL ASSESSMENT OF THE FIBRINOLYTIC STATUS
In the absence of a physiologically relevant global test, fibrinolytic status has been assessed using the factorial approach. A number of fibrinolytic parameters are measured, such as t-PA and PAI-1 antigen and activity, alpha2-antiplasmin (alpha2-AP), plasminogen, total activator activity (i.e., the ability of plasma to activate plasminogen), serum D-dimer, cross-linked fibrin degradation products (FDP), thrombin-activatable fibrinolysis inhibitor (TAFI), and protein C. t-PA is the major plasminogen activator responsible for dissolving blood clots or thrombus (24) . Paradoxically, an increase in the concentration of t-PA antigen has been documented during the subacute phase of AMI and this was suggested to be a predictor of recurrent infarction, sudden cardiac death (30) and long-term mortality in patients with coronary artery disease (31) . As PAI-1 activity was found to be significantly and positively associated with t-PA concentration (32) , the documented increased mass concentration of t-PA in patients with cardiovascular events is probably attributable to an inactive enzyme inhibitor complex (t-PA/PAI-1). Plasma D-dimer concentration detects ongoing fibrinolysis and as such, it is very useful in diagnosing hypercoagulable states such as deep venous thrombosis and/or pulmonary embolism. However, elevated D-dimer concentrations have been reported in several clinical settings (33) , which confound the diagnostic usefulness of this assay. Not only are these tests laborious and time-consuming, but from the results, it is practically impossible to assess the overall spontaneous fibrinolytic activity of an individual patient, that is, the capacity of blood to prevent occlusion or restore vessel patency in case of a thrombotic event.
DIFFERENCES BETWEEN CLOT AND THROMBOLYSIS
Venous (red cell rich) thrombi and arterial (platelet-rich) thrombi have differing sensitivities to lysis. A platelet-rich thrombus is much more resistant to lysis with rt-PA than a venous one (34) . This is because upon activation, platelets release PAI-1, a rapid inhibitor of tPA (35) . Platelets contain approximately 90% of the total amount of PAI-1 present in blood (36) . When activated, platelets aggregate and release functionally active PAI-1 and with this, confer re-sistance on such platelet-rich thrombi to natural lysis. Analysis of proteins of the fibrinolytic system in human thrombi demonstrated PAI-1 and alpha2-AP in the thrombus in high concentrations. The abundant PAI-1 was associated primarily with platelets, but also with fibrin. The alpha2-AP concentration in thrombus was similar to the high plasma concentration, whereas PAI-1 levels were up to 30 times greater than that in circulating blood. In contrast, levels of t-PA and t-PA/PAI-1 complex were relatively low (37) . High concentrations of active PAI-1 have also been described in porcine coronary artery thrombi (38) . Furthermore, platelets contain TAFI that is secreted during platelet activation (39) and platelet-derived TAFI has been implicated in the protection of thrombi against fibrinolysis. It seems therefore, that the major competing players in the lysis of a platelet-rich thrombus are, on the one hand, the circulating polymorphonuclear leucocytes, which incorporate into the thrombus and contribute significantly to the endogenous lysis process (40) , and on the other, the powerful inhibitors (PAI-1, TAFI) released from platelets.
SIGNIFICANCE OF MEASURING SPONTANEOUS THROMBOLYTIC ACTIVITY
Clinical and laboratory data suggest great individual variation in the efficacy of spontaneous thrombolysis. Only a small fraction of people presenting with typical chest pain develop AMI. Recovery from an acute ischemic stroke and the extent of lasting tissue damage also shows great individual differences. Altered spontaneous fibrinolytic activity has been found in several conditions with thrombotic manifestations. Measurement of plasma levels of plasminogen activators and inhibitors suggests impaired endogenous fibrinolytic potential in diabetes (41) , multiple sclerosis (42) , severe sepsis and inflammation (43) , and enhanced in advanced cirrhosis (44) . No drugs are in use with a specific indication for boosting or restoring endogenous fibrinolytic potential. Nevertheless, long-term medication of diabetes with metformin (45), lipidlowering in atherosclerosis using statins (46) , antihypertensive therapy (47) , hormone replacement (48) , and physical exercise (49) have been shown to activate endogenous fibrinolysis. Great variation exists between individuals in the plasma levels of the components of the fibrinolytic system. The range of PAI-1 activity and PAI-1 antigen levels in patients admitted to coronary care unit with acute chest pain and a tentative diagnosis of AMI was enormous (1.5-118.5 IU/mL activity and 8.1-132.2 ng/mL antigen) (50) . The cause of this variation can be hereditary or acquired (51) . Plasma TAFI concentration has been shown to be almost entirely genetically determined (52) . Homozygous, but not heterozygous, alpha2-AP-deficient patients exhibit enhanced spontaneous lysis and manifest a bleeding tendency (53) . Genetic variations in PAI-1 are associated with increased or decreased plasma PAI-1 levels and accordingly the risk of a thrombotic event is increased or reduced (54) (55) (56) . Thus, the use of a global test for timely diagnosis of inefficient or lack of spontaneous thrombolytic activity would have great potential in the prevention and in the treatment of thrombosis.
TECHNIQUES TO ASSESS SPONTANEOUS THROMBOLYTIC ACTIVITY
There is no global in vitro test in routine clinical use that would allow the measurement of thrombolysis, as opposed to clot lysis. Such test should involve the formation of an autologous platelet-rich thrombus under physiologic conditions and then the subsequent measurement of disruption/degradation/lysis of such thrombus.
Recently a new, commercially available global thrombosis test (GTT; Montrose Diagnostics Ltd., UK, www.montroseltd.net) has been described (57) . This technique is unique for testing thrombus formation by high shear stress in native, nonanticoagulated blood (58) . The first phase of the test (end-point: occlusion time) provides a true assessment of physiologic platelet function including aggregation and platelets' coagulant activity. Evidence has been presented that restart of blood flow following occlusion is due to thrombolysis (end-point: lysis time). This test sensitively detected not just plasminogen activator-induced hyperfibrinolysis, but also the spontaneous lysis of a platelet-rich thrombus (59) . The latter occurs in less than an hour, a time frame acceptable both in the laboratory and in clinical settings. In Japanese volunteers of different age groups, spontaneous thrombolysis was significantly impaired in elderly male but not in female. It was suggested that this could be an explanation for the well-established gender differences in risk of acute coronary syndromes (60) .
Thus this technique seems suitable to study populations at large, particularly to screen for conditions known to adversely affect the endogenous fibrinolytic system.
